219 related articles for article (PubMed ID: 22154383)
1. Home treatment of hereditary angioedema with icatibant administered by health care professionals.
Farkas H; Csuka D; Zotter Z; Varga L; Böröcz Z; Temesszentandrási G; Jakab L; Karádi I
J Allergy Clin Immunol; 2012 Mar; 129(3):851-852.e2. PubMed ID: 22154383
[No Abstract] [Full Text] [Related]
2. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
4. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
Krause K; Metz M; Zuberbier T; Maurer M; Magerl M
J Dtsch Dermatol Ges; 2010 Apr; 8(4):272-4. PubMed ID: 19758369
[TBL] [Abstract][Full Text] [Related]
6. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
Piras V; Alves F; Gonçalo M
Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
[TBL] [Abstract][Full Text] [Related]
7. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
[TBL] [Abstract][Full Text] [Related]
8. In brief: icatibant (Firazyr) for hereditary angioedema.
Medical Letter
Med Lett Drugs Ther; 2011 Nov; 53(1378):96. PubMed ID: 22113125
[No Abstract] [Full Text] [Related]
9. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
[TBL] [Abstract][Full Text] [Related]
10. Icatibant for the treatment of hereditary angioedema.
Cole SW; Lundquist LM
Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
[TBL] [Abstract][Full Text] [Related]
11. Kinin formation in C1 inhibitor deficiency.
Kaplan AP; Joseph K
J Allergy Clin Immunol; 2010 Jun; 125(6):1411-2; author reply 1412. PubMed ID: 20381848
[No Abstract] [Full Text] [Related]
12. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week.
Bork K; Hardt J
Int Arch Allergy Immunol; 2011; 154(1):81-8. PubMed ID: 20664282
[TBL] [Abstract][Full Text] [Related]
13. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
14. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks.
Bouillet L; Boccon-Gibod I; Ponard D; Drouet C; Cesbron JY; Dumestre-Perard C; Monnier N; Lunardi J; Massot C; Gompel A
Ann Allergy Asthma Immunol; 2009 Nov; 103(5):448. PubMed ID: 19927548
[No Abstract] [Full Text] [Related]
15. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR
Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340
[TBL] [Abstract][Full Text] [Related]
16. Management of acute attacks of hereditary angioedema: potential role of icatibant.
Longhurst HJ
Vasc Health Risk Manag; 2010 Sep; 6():795-802. PubMed ID: 20859548
[TBL] [Abstract][Full Text] [Related]
17. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE; Sheffer AL
Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
19. [Allergy-immunology. New therapies for acute attacks in hereditary angioedema].
Leimgruber A
Rev Med Suisse; 2011 Jan; 7(278):103-5. PubMed ID: 21400938
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
Bork K; Frank J; Grundt B; Schlattmann P; Nussberger J; Kreuz W
J Allergy Clin Immunol; 2007 Jun; 119(6):1497-503. PubMed ID: 17418383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
